Considering FY22 earnings, the company demands a price-earnings (P/E) multiple of 105. It has no listed peers. Given the size of its operations, valuation appears to be steep though skewed by a sharp fall in the profit due to the pandemic. Considering the pre-pandemic profit level, the P/E works out to be around 55.
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength.
May 25, 2026